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The discovery of novel ligands for orphan GPCRs has profoundly affected our under-
standing of human biology, opening new opportunities for research, and ultimately
for therapeutic development. Accordingly, much effort has been directed towards
the remaining orphan receptors, yet the rate of GPCR de-orphanisation has slowed
in recent years. Here, we briefly review contemporary methodologies of de-
orphanisation and then highlight our recent integrated computational and experimen-
tal approach for discovery of novel peptide ligands for orphan GPCRs. We identified
putative endogenous peptide ligands and found peptide receptor sequence and
structural characteristics present in selected orphan receptors. With comprehensive
pharmacological screening using three complementary assays, we discovered novel
pairings of 17 peptides with five different orphan GPCRs and revealed potential addi-
tional ligands for nine peptide GPCRs. These promising findings lay the foundation
for future studies on these peptides and receptors to characterise their roles in
human physiology and disease.
1 | GPCRS AND DE-ORPHANISATION
Approximately 30% of the ~400 non-olfactory human GPCRs have not
been definitively paired with endogenous ligands and are designated as
“orphan” receptors (Alexander et al., 2019; Laschet, Dupuis, & Hanson,
2018). These receptors represent a wealth of unexplored biology and
are likely to be involved in physiological and disease processes (Figure 1).
As a recent case-in-point, rare-variant genomic analyses of a large clini-
cal population have recently identified disease associations for numer-
ous orphan GPCRs (Dershem et al., 2019). Equally, as around one third
of FDA-approved drugs mediate their effects via GPCRs (Hauser,
Attwood, Rask-Andersen, Schiöth, & Gloriam, 2017), orphan receptors
also hold considerable promise for drug discovery programmes.
GPCR de-orphanisation—that is, pairing a GPCR with its endoge-
nous ligand(s)—reached its zenith in the late 1990s and early 2000s,
Abbreviations:MS, mass spectrometry.
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with the coalescence of significant investment from the pharmaceuti-
cal industry, development of high-throughput reverse pharmacology
approaches, and sequencing of the human genome. This period saw
around 10 de-orphanisations each year, including several success
stories that have progressed through drug discovery pipelines to
become the targets of approved therapeutic agents, such as neuro-
kinin and orexin receptors (Civelli et al., 2013). However, despite
advances in GPCR research, progress in de-orphanisation
has slowed in the intervening years (www.guidetopharmacology.org/
latestPairings.jsp; for reviews, see Alexander et al., 2019;
Civelli et al., 2013; Laschet et al., 2018). On one hand, this is unsur-
prising as, inter alia, those targets exhibiting high protein sequence
homology with liganded receptors or those responding to known
physiological ligands have already been paired. On the other hand, an
inherent problem with orphan GPCRs is that their function and
signalling pathway(s) are typically unknown. This has necessitated
methods utilising chimeric G proteins or β-arrestin recruitment assays
that direct cellular responses to a discrete readout of receptor
activation (Ozawa, Lindberg, Roth, & Kroeze, 2010). Given the
pleiotropic nature of GPCR signalling, these approaches may have
overlooked important receptor–ligand interactions. Indeed, a
β-arrestin recruitment assay screen of ~5,300 candidate endogenous
ligands against 82 orphan receptors only identified a single proposed
orphan GPCR ligand (Southern et al., 2013). Accordingly, new and
different strategies are required to discover the endogenous ligands
for the remaining intractable orphan GPCRs.
F IGURE 1 Knowledge state for class A orphan GPCRs. There are 84 class A orphans receptors (excluding tentative pseudogenes), as
classified by IUPHAR Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR). These receptors generally have low
sequence similarity to non-orphans, making it more challenging to garner reliable data on their evolutionary history or 3D structure than for
other GPCRs. Nonetheless, 34 orphan receptors have proposed endogenous ligands (yellow boxes), whereas the majority do not (black
boxes). Gene expression data reveals abundant and ubiquitous tissue expression for many orphan receptors (Lachmann et al., 2018; green
ring, darker shading denotes higher abundance). Aggregated disease associations for orphan receptors from OpenTargets (Carvalho-Silva et al.,
2019) highlight the clinical relevance and therapeutic potential across disease areas (purple ring, darker shading denotes stronger association).
Inner ring: orphan GPCR publication/knowledge scores (black) and tool compounds listed on the ChEMBL database (blue; Nguyen et al.,
2017)
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2 | APPROACHES FOR PEPTIDE-GPCR DE-
ORPHANISATION
Peptide ligands and hormones are fundamental physiological media-
tors that primarily act on GPCRs. Given their involvement in diverse
physiological processes, intensive research has been directed towards
the identification of peptide receptors and their corresponding endog-
enous peptide ligands. Indeed, following completion of the human
genome, it became clear that the number of peptide receptors
exceeded the known peptide ligands (Civelli et al., 2013). Likewise,
based on the fraction of peptide-activated receptors, ~25 class A
orphan GPCRs were estimated to have endogenous peptide ligands
(Vassilatis et al., 2003). This stimulated renewed experimental and bio-
informatic efforts to identify candidate peptide precursors and
peptides.
There have been some notable successes, including peptide
ligands for GPR83 and GPR171, which have been implicated in
feeding behaviours in mice (Gomes et al., 2013; Gomes et al.,
2016). To this end, mass spectrometry (MS) has enabled the dis-
covery of several bioactive peptides (Fricker et al., 2000; Hatcher
et al., 2008), even though it is very difficult to detect the inher-
ently limited temporal and spatial expression of secreted peptides
in mixed samples containing large quantities of other proteins. MS
has been applied to peptide ligand screening, as it is label-free and
unbiased with respect to signalling pathways (Yen et al., 2017).
Recently, HPLC and MS of bile and cell culture supernatants
have led to the discovery of a post-translationally modified peptide,
S-geranylgeranyl-L-GSH as a potent endogenous ligand for the
orphan receptor P2RY8 (Lu, Wolfreys, Muppidi, Xu, & Cyster,
2019).
The genetic encoding of peptide sequences affords great oppor-
tunities for the development of sequence-based computational
methods to identify novel peptides and precursors. These include ana-
lyses of shared motifs within precursors (Baggerman, Liu, Wets, &
Schoofs, 2005) and the development of probability-based models
using common peptide sequence features (Mirabeau et al., 2007).
These computational approaches led to the discovery of spexin and
augurin as proposed (although not yet confirmed) endogenous ligands
for galanin receptors and scavenger receptors respectively. These suc-
cesses notwithstanding, it remains challenging to accurately predict
novel peptide ligands using knowledge of existing ligands and sequence
data (Ozawa et al., 2010), particularly due to the extensive post-
translational processing of peptides and the complexity of peptide–
receptor signalling.
F IGURE 2 Discovery of novel peptides for orphan GPCRs. Putative peptide orphan receptors were selected based on molecular sequence
characteristics (top left). An endogenous peptide library was designed from evolutionary tracing and putative cleavage sites found within potential
precursor proteins (bottom left); 218 peptides were screened against 21 orphan GPCRs in three independent functional assays covering multiple
signalling pathways (middle). Five orphan GPCRs (GPR1, GPR15, GPR55, GPR68, and BB3) were paired with 17 peptides and validated in at least
two orthogonal assays (examples on the right). These novel peptide–receptor interactions represent unexplored aspects of human physiology
with considerable implications for drug discovery efforts
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3 | IDENTIFICATION OF CANDIDATE
ENDOGENOUS PEPTIDES AND ORPHAN
RECEPTOR TARGETS
We have recently embarked on a large combined computational
and experimental approach to identify orphan GPCR ligands
(Figure 2; Foster et al., 2019). Predicated on the hypothesis that
there are undiscovered endogenously produced peptide ligands for
orphan receptors, we began by collecting all publicly available infor-
mation on known endogenous receptor–ligand pairings. Our quanti-
tative analyses demonstrated that endogenous peptide ligands far
outnumber endogenous small molecule ligands, are larger, and often
have higher affinity to their cognate receptors. Evolutionary ana-
lyses across hundreds of eukaryotic organisms revealed that co-
evolution of peptide ligand–receptor pairs has made peptides the
most adaptive, widely utilised, and versatile type of human signal-
ling molecules.
Building on these observations, we identified defining sequence
and structural characteristics for peptide ligands and receptors and
then leveraged these to mine the human proteome for potential
peptide ligands and predicted putative peptide-binding receptors. In
brief, we queried the proteome for new peptide ligand precursors
based on secretion motifs and combined this with evolutionary
conservation analyses of all known peptide ligands and their pre-
cursors. This revealed that peptide-coding regions are considerably
more conserved than other parts of the precursor. Hence, using a
machine-learning model and prioritising the most conserved regions
of each precursor candidate between conserved dibasic cleavage
motifs, we generated a library of putative endogenous peptide
ligands for experimental testing. The final library comprised
218 custom-synthesised peptides, including 49 known peptide
ligands for class A GPCRs. In parallel, based on molecular sequence
signatures of known peptide receptors, we predicted the class A
orphan receptors most likely to be activated by peptides, and
selected 21 for further characterisation.
To maximise the likelihood of capturing peptide-dependent
orphan GPCR activation, regardless of signalling pathway, we eval-
uated our putative endogenous peptide ligands in three parallel
assay platforms: dynamic mass redistribution (Schröder et al.,
2011), real-time receptor internalisation (Foster & Bräuner-Osborne,
2018), and β-arrestin recruitment (PRESTO-Tango; Kroeze et al.,
2015). Each of these assays has strengths and limitations individu-
ally: Dynamic mass redistribution assays detect G protein-mediated
responses from endogenously expressed proteins, as well as over-
expressed receptors, but do not directly measure β-arrestin signal-
ling (Grundmann et al., 2018). The internalisation assay can detect
β-arrestin-dependent and independent trafficking but relies on an
N-terminal SNAP tag which could potentially modulate ligand bind-
ing. The Tango assay is a sensitive downstream genetic readout
for β-arrestin recruitment, although the signal amplitude varies
between receptors and it does not report activation for all GPCRs
(Kroeze et al., 2015). For logistical reasons, our screens were per-
formed in recombinant expression systems (e.g., modified HEK
cells), and it is conceivable that these could lack required signalling
partners for orphan receptors. However, in combination, these
assays provide complementary coverage of GPCR-mediated signal-
ling and overcome significant limitations of previous de-
orphanisation efforts.
4 | NEW PEPTIDE LIGANDS FOR ORPHAN
GPCRS
Using our multifaceted experimental approach, we paired five
“orphan” receptors with 17 peptides that represent potential novel
endogenous ligands (Foster et al., 2019) (Table 1). These include pep-
tides for GPR1, GPR15, GPR55, GPR68, and BB3 receptors, validated
in at least two orthogonal assays (discussed below). We also identified
indicative pairings for five other orphan receptors using the β-arrestin
recruitment assay and potential secondary peptide ligands for nine
known peptide GPCRs. Conversely, we identified nine peptides that
elicited clear responses in background cells, which could be consid-
ered as “orphan peptides” without a currently known endogenous
GPCR or non-GPCR target.
4.1 | GPR1
We discovered three peptides that robustly activated GPR1 (recently
renamed chemerin receptor 2; Kennedy & Davenport, 2018). These
include a new peptide derived from the osteocrin precursor and
two known peptides gastrin-releasing peptide and cholecystokinin.
Consistent with published reports (Alexander et al., 2019), these
responses were confirmed in two different β-arrestin recruitment
assays, while no G protein signalling was observed. These findings
suggest that GPR1 is a β-arrestin biased receptor, which will be of
interest to clarify in future studies, particularly given the broad
expression profile and pathophysiological implications for GPR1/
chemerin2 (Kennedy & Davenport, 2018).
4.2 | GPR15
We identified a novel 11-amino acid peptide derived from an
uncharacterised gene C10orf99 as a GPR15 ligand. We then investi-
gated longer peptide variants and identified a 57-residue peptide as
the most potent GPR15 ligand. During the course of our project, this
same pairing was independently reported by Novartis and confirmed
by another research group (Ocon et al., 2017; Suply et al., 2017), and
this ligand has since been renamed as GPR15L. Nonetheless, whereas
Suply et al. (2017) isolated GPR15L from pig colon, we used an
entirely different computational approach that discovered additional
peptide cleavage variants demonstrating the importance of the
carboxy-terminus (Foster et al., 2019). The GPR15 and GPR15L sig-
nalling axis is an emerging therapeutic target for colon and skin
inflammation (Suply et al., 2017).
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4.3 | GPR55
We identified five novel peptides and PACAP-27 as GPR55 ligands
using unbiased mass redistribution and internalisation assays. Intrigu-
ingly, PACAP-27 (a known class B receptor ligand) activated GPR55
with comparable picomolar potency to its cognate receptor PAC1
(Alexander et al., 2019). GPR55 preferentially couples to G12/13 and is
a challenging receptor target, so further studies are required in G pro-
tein assays and relevant physiological contexts. Equally, the potential
interaction of GPR55 with PAC1 is worthy of investigation, particu-
larly given the recent description of crosstalk between the μ-opioid
receptor and the orphan receptor GPR139 (Wang et al., 2019).
4.4 | GPR68
GPR68 is a proton-sensing GPCR that is currently attracting interest
as a potential target for airway inflammation, CNS disorders, and can-
cer (Huang et al., 2015). Nonetheless, we observed that GPR68 dis-
plays many characteristics of peptide-activated GPCRs (Foster et al.,
2019), and we discovered multiple peptides that potentiate the
proton-mediated GPR68 signalling. These include undescribed pep-
tide variants from osteocrin and cocaine- and amphetamine-regulated
transcript protein precursors. These ligands represent the first peptide
positive allosteric modulators of GPR68, with approximately twofold
improved allosteric activity (log (ab/KB)) over the small molecule com-
pound ogerin (Huang et al., 2015).
4.5 | BB3
The bombesin family receptor BB3 is weakly activated by
bombesin-like peptides and has been previously described as a
“reluctant de-orphanisation” (Civelli et al., 2013). In our study, we
identified neuromedin B and gastrin-releasing peptide-dependent
BB3 activation at high nanomolar concentrations, more potent than
previously reported, but still lower potency than for the BB1 recep-
tor. As receptor knockout mice develop mild obesity, BB3 receptors
have been implicated in feeding behaviour regulation, potentially in
concert with other bombesin receptors (Civelli et al., 2013).
Interestingly, due to its constitutive activity, BB3 receptors
have recently been suggested to lack an endogenous ligand (Tang
et al., 2019).
Collectively, our study has yielded new insights into human pep-
tidergic receptor signalling and revealed several novel putative endog-
enous peptide–receptor interactions. These pairings require additional
research to determine their physiological relevance including, ulti-
mately, supporting in vivo studies. As many orphan receptors were
activated with low potency, these may be considered as lead peptides
for future studies, as the precise physiologically relevant cleavage var-
iant and post-translational modifications for these peptides remain to
be identified. We would therefore encourage further characterisation
of our proposed peptide–receptor pairings, in particular by testing
peptide variants in relevant biological systems with endogenous
receptor expression.
Our identification of new peptide–receptor pairings strongly vali-
dates our combinatorial computational and experimental approach
for GPCR de-orphanisation. Nonetheless, in light of the vast number
of potential peptides encoded in the human proteome and the per-
mutations of post-translational modifications, it is possible that the
optimal peptide ligands (or peptide-activated receptors) were not
tested. Moreover, we could not account for peptide cleavage and
truncation, for example, by plasmin and dipeptidyl peptidase-4,
which is important for other endogenous neuropeptide and chemo-
kine ligands (Richter et al., 2009; Torang et al., 2016). Interestingly,
new large-scale transcriptome and proteome studies now have
improved coverage of human peptides and proteins, which may also
lead to the discovery of previously unappreciated protein products
(Jiang et al., 2019). Orphan receptors may also require additional sig-
nalling partners that were absent from our experimental setups, such
as other GPCRs or receptor activity-modifying proteins (Lorenzen
et al., 2019; Wang et al., 2019). Alternatively, these receptors may
not have peptide ligands or be constitutively active (Martin, Steurer, &
Aronstam, 2015), or their activating molecules may be produced
exogenously, as suggested for microbiome-derived ligands for
GPR119 (Cohen et al., 2017). These are all potential areas for future
investigation.
5 | CONCLUDING REMARKS
The discovery of new orphan GPCR ligands regularly has substantial
impact, and each of our peptide–receptor pairings opens up new ave-
nues of research. Indeed, all paired receptors and the majority of their
peptide ligands have been implicated in disease, suggesting high trans-
lational potential to druggable targets and ligands. Hence, our new
approach and findings will have broad appeal and effects across
research fields and therapeutic areas.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al.,
2019).
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